Pharma News, 2024

AstraZeneca’s (AZ) Voydeya (danicopan) has been approved by the US Food and Drug Administration (FDA) as an add-on therapy for paroxysmal nocturnal haemoglobinuria (PNH&#...

Ipsen signed a licensing agreement to develop and commercialise Sutro Biopharma’s ADC STRO-003 intended as a treatment for solid tumours.

More than half of patients with treatment-resistant depression achieved response with a single dose of BPL-003, a benzoate salt formulation of 5-MeO-DMT (мebufotenin benzoate) that is adminis...

XIlio Therapeutics has implemented cost-cutting measures which include a 21% workforce reduction and the termination of investments for developing one of its assets, XTX202, as a monotherapy.

A Swiss-based medical technology company has announced a partnership with Biogen to advance a digital biomarker platform involved in a planned clinical trial for BIIB122, a novel therapeutic to treat ...

Adagrasib monotherapy improved PFS and overall response rate among adults with pretreated locally advanced or metastatic non-small cell lung cancer harboring a KRASG12C-mutation, according to results ...

The European Commission (EC) has approved Otsuka Pharmaceutical Europe and H Lundbeck’s Abilify Maintena 720mg/960mg (aripiprazole) for the maintenance treatment of schizophrenia.

Bristol Myers Squibb (NYSE: BMY) today announced an update following the initial analysis of results from the first of two induction studies in the Phase 3 YELLOWSTONE clinical trial program e...

The FDA approved cobas Malaria (Roche) for use on the cobas 6800/8800 systems to assist health care professionals in reducing the potential risks of patient infection from transfused blood pro...

The FDA granted Orphan Drug Designation (ODD) to utidelone injectable (UTD1; Biostar Pharma) to treat breast cancer (BC) brain metastasis (BM). The recent ODD for the u...

The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved AstraZeneca‘s Truqap (capivasertib) plus Faslodex (fulvestrant) for a specific type of breast cancer.

Akebia Therapeutics®, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the U.S.